2015
Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors
Sullivan K, Bolton-Gillespie E, Nieborowska-Skorska M, Cerny-Reiterer S, Valent P, Muschen M, Pomerantz R, Mazin A, Skorski T. Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors. Blood 2015, 126: 50. DOI: 10.1182/blood.v126.23.50.50.Peer-Reviewed Original ResearchQuiescent leukemia stem cellsLeukemia stem cellsTyrosine kinase inhibitorsChronic myeloid leukemiaCML cellsBCR-ABL1Myeloid leukemiaAnti-leukemia effectSimultaneous targetingCML leukemia stem cellsNew treatment modalitiesPARP1 inhibitorsCML stem cellsNormal counterpartsDouble knockout miceAdditional chromosomal aberrationsTKI-resistant BCRStem cellsBristol-Myers SquibbTKI therapyDisease relapseChronic phaseGood respondersCML patientsTreatment modalities
2010
Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia
Park E, Jiang E, Hsieh Y, Klemm L, Duy C, Conway E, Pelus L, Crispino J, Loh M, Kang E, Koo H, Yang A, Heisterkamp N, Kahn M, Muschen M, Kim Y. Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia. Blood 2010, 116: 3263. DOI: 10.1182/blood.v116.21.3263.3263.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaMedian survival timeLymphoblastic leukemiaLong-term side effectsNucleic acid antisense oligonucleotideRelapse of leukemiaSurvivin shRNASingle-agent treatmentNew treatment modalitiesNOD/SCIDEvaluation of survivinInhibition of survivinCFU assayBone marrow cellsGFP controlFunction studiesKnockout mouse modelOverexpression of survivinAmgen IncLNA treatmentLeukemia relapseKnockdown of survivinTreatment modalitiesCurrent treatmentMouse model